Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Genitourinary tumours, prostate

612MO - Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study

Date

18 Sep 2020

Session

Mini Oral - Genitourinary tumours, prostate

Presenters

Rebeca Lozano Mejorada

Citation

Annals of Oncology (2020) 31 (suppl_4): S507-S549. 10.1016/annonc/annonc275

Authors

R. Lozano Mejorada1, E. Castro Marcos2, I.M. Aragon1, H. Thorne3, F. Lopez Campos4, A. Sanz1, C. Alonso5, U. Anido6, M.J. Juan Fita7, A.M. Gutierrez Pecharromán8, M. Ramirez-Backhaus9, J. Balmana10, I. Chirivella Gonzalez11, G. Llort12, N. Romero Laorden5, S. Arevalo Lobera13, J. Rubio Briones9, C.C. Pritchard14, S. Sandhu3, D. Olmos Hidalgo1

Author affiliations

  • 1 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 - Madrid/ES
  • 2 Medical Oncology, Hospital Universitario Virgen de la Victoria; Instituto de Investigación Biomédica de Málaga, 29010 - Málaga/ES
  • 3 Medical Oncology, Peter MacCallum Cancer Centre, Melbourne/AU
  • 4 Radiation Oncology Department, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 5 Medical Oncology Department, Hospital Universitario de la Princesa, 28006 - Madrid/ES
  • 6 Medical Oncology Department, CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706 - Santiago de Compostela/ES
  • 7 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 8 Pathology, Hospital de Getafe, Getafe/ES
  • 9 Urology Department, Fundación Instituto Valenciano de Oncologia, 46009 - Valencia/ES
  • 10 4. hereditary Cancer Genetics Group, Vhio. Medical Oncology Department, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 11 Medical Oncology Department, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 12 8. hereditary Cancer Unit And Medical Oncology Department, Corporació Sanitaria Universitària Parc Taulí de Sabadell and Consorci Sanitari de Terrassa, Barcelona/ES
  • 13 Medical Oncology Department, Hospital Donostia, 20014 - San Sebastian/ES
  • 14 Laboratory Medicine, University of Washington, WA 98109 - Seattle/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 612MO

Background

Germline BRCA2 mutations (gBRCA2) are associated with poor clinical outcomes in prostate cancer (PC), however, the molecular origin of this clinical aggressiveness have not been fully elucidated.

Methods

In this multicentre case-control study, gBRCA2 carriers were matched 1:2 to known non-carriers (NC) by Gleason score and stage at diagnosis (M0 vs M1). A minimum of 60 cases-120 controls were required to prove a 5yrs cause-specific survival (CSS) rate of 60% vs 85%. The primary aim was to confirm the independent prognostic role of gBRCA2 in PC CSS. Secondary aims included to explore the clinical impact of somatic events in BRCA2, RB1, MYC, PTEN and TMPRSS2-ERG by FISH. Kaplan Meier and Cox-regression models were used to identify associations between molecular characteristics and outcomes.

Results

A total of 73 gBRCA2 carriers and 127 NC were eligible. gBRCA2 carriers were younger at diagnosis (p=0.02) and had more often T3/4 (p<0.001) than NC, but no other significant differences were found. gBRCA2 carriers presented more somatic alterations than NC (p<0.001), including BRCA2 loss, RB1 loss and MYC amplification. BRCA2 were frequently co-deleted with RB1 (Pearson correlation 0.96; p=0.001). gBRCA2 mutations were independently associated with CSS (HR 3.70; p=0.008). CSS were shorter in gBRCA2 carriers who also present somatic BRCA2-RB1 codel or MYC amplification compared with gBRCA2 without such alterations. SImilar results were observed in NC (Table). MVA model confirmed the independent prognostic value of somatic BRCA2-RB1 codel (HR 4.13; p=0.004) and MYC amplif (HR 2.27; p=0.033) for CSS. Table: 612MO

Median CSS (96%CI), yrs p-value
gBRCA2 gBRCA2 + BRCA2-RB1 codeletion 11.3 (7-2-15.4) 6.3 (2.1-10.6) 0.041
gBRCA2 gBRCA2 + MYC amplification 13.4 (10-16.8) 6 (4.1-7.9) <0.001
NC NC + BRCA2-RB1 codeletion 17.6 (NR) 9.8 (5.9-13.8) <0.001
NC NC + MYC amplification 17.6 (NR) 4.8 (0-10.8) <0.001

Conclusions

PROREPAIR-A is the largest series of gBRCA2 tumors assembled to date to explore associations between somatic alterations and clinical outcomes in PC. Our results suggest that somatic BRCA2-RB1 codel and MYC amplification define an aggressive subtype of PC with poor clinical outcomes in both gBRCA2 and NC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Spanish National Cancer Research Centre (CNIO).

Funding

CRIS Foundation, Prostate Cancer Foundation PCF Foundation.

Disclosure

R. Lozano Mejorada: Speaker Bureau/Expert testimony: Roche, Janssen-Cilag, Sanofi; Travel/Accommodation/Expenses: Roche, Janssen-Cilag, Astellas Pharma. E. Castro Marcos: Honoraria (self): Astellas Pharma, AstraZeneca, Bayer, Janssen-Cilag, Pfizer; Advisory/Consultancy: AstraZeneca, Bayer, Janssen; Research grant/Funding (institution): AstraZeneca, Bayer, Janssen; Travel/Accommodation/Expenses: Bayer, Janssen-Cilag, Roche, Astellas Pharma. F. Lopez Campos: Advisory/Consultancy: Astellas Pharma; Speaker Bureau/Expert testimony: Janssen, Astellas Pharma; Travel/Accommodation/Expenses: Astellas Pharma, Janssen; Research grant/Funding (self): Astellas Pharma. U. Anido: Honoraria (self): Pfizer, Novartis, Bayer, Bristol-Myers-Squbb, EUSA Pharma, Eisai, Astellas Pharma, Jassen-Oncology, Sanofi; Advisory/Consultancy: Bayer, Pfizer, Novartis, Ipsen, Eisai, EUSA Pharma, Sanofi; Research grant/Funding (self): Pierre Fabre; Travel/Accommodation/Expenses: Astellas Pharma, Novartis, Roche, Pfizer, Ipsen, Sanofi. M.J. Juan Fita: Advisory/Consultancy: Janssen; Speaker Bureau/Expert testimony: Sanofi, Astellas, Janssen, BMS, Bayer; Travel/Accommodation/Expenses: Janssen. N. Romero Laorden: Research grant/Funding (institution), Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy: Janssen, IPSEN, Astellas, Astra-Zeneca, MSD, Bayer, Tesaro, Sanofi. J. Rubio Briones: Advisory/Consultancy: Janssen, Astellas, Bayer; Research grant/Funding (self): HealthMDx. C.C. Pritchard: Advisory/Consultancy: AstraZeneca, Promega. D. Olmos Hidalgo: Honoraria (self): Bayer, Janssen, Sanofi; Advisory/Consultancy: AstraZeneca, Bayer, Clovis Oncology, Daiichi-Sankyo, Janssen, MSD, Roche ; Research grant/Funding (institution): Astellas, AstraZeneca, Bayer, Genentech, Janssen, Medication, MSD, Pfizer, Roche, Tokai Pahrmaceutics; Travel/Accommodation/Expenses: Bayer, Ipsen, Janssen, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings